The vaccine for cervical cancer to

   This is an important vaccine to combat a disease that causes the death of about 300,000 women every year around the world. The Gardasil, is manufactured by Merck & Co. Inc. and intended for girls and young women between the ages of 9 and 26 years. The drug acts on certain types of papillomavirus (HPV), a micro-organism that transmits easily with sexual activity and that can cause this type of cancer. According to a. von Eschenbach (Food and Drug Administration), the vaccine is a significant step forward in protecting the health of women. Administered in three doses over six months, Gardasil hits four types of HPV that are believed to be at the base by more than 70% of cervical cancer. HPV infects about half of sexually active adults, but is usually harmless. In most advanced Nations, preventive controls have reduced the incidence of this disease, which is widespread in developing countries. According to studies conducted by Merck, the vaccine can prevent all injuries precancerous in cervix, vagina and vulva. According to the FDA, is therefore very likely that the drug is effective in the prevention of cancer to the cervix. However, it is not yet known how long the effectiveness of the drug over time. Surely the administration of the vaccine does not eliminate the need to undergo periodic inspections. Currently other research are underway to evaluate the effectiveness of the medication on women after 26 years and men and is considering recommending the spread of HPV vaccination. According to FDA, early treatment is appropriate because the drug is effective only if administered before infection; also the spread of the vaccine could be particularly useful in poorer nations, where there is the possibility of adopting other methods of control. Merck was available to provide low-cost vaccine for distribution in poor areas of the planet. A similar vaccine is being developed by GlaxoSmithKline